We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Morphological and Functional Evaluation of Buttock Lipoatrophy Treatment With Macrolane

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00931268
First Posted: July 2, 2009
Last Update Posted: December 19, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Q-Med AB
Results First Submitted: July 12, 2013  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Atrophy
Intervention: Device: Macrolane VRF 30

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
First subject enrolled (screened) and treated: 11 August 2009. Last subject completed study: 2 September 2011.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Macrolane VRF 30 Open label, baseline-controlled, one treatment session with injection of Macrolane VRF30 to each buttock, not exceeding 400 ml per subject.

Participant Flow:   Overall Study
    Macrolane VRF 30
STARTED   10 
COMPLETED   4 
NOT COMPLETED   6 
Lost to Follow-up                6 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Macrolane VRF 30 Open label, baseline-controlled, one treatment session with injection of Macrolane VRF30 to each buttock, not exceeding 400 ml per subject.

Baseline Measures
   Macrolane VRF 30 
Overall Participants Analyzed 
[Units: Participants]
 10 
Age 
[Units: Participants]
 
<=18 years   0 
Between 18 and 65 years   10 
>=65 years   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 44.6  (3.7) 
Gender 
[Units: Participants]
 
Female   5 
Male   5 
Region of Enrollment 
[Units: Participants]
 
France   10 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change From 6 Months to Baseline in Visual Analogue Scale (VAS) Pain After 15 Minutes of Sitting   [ Time Frame: 6 months after treatment compared to baseline ]

2.  Secondary:   Change From up to 18 Months to Baseline in Visual Analogue Scale (VAS) Pain After 15 Minutes of Sitting   [ Time Frame: Baseline and up to 18 months after treatment ]

3.  Secondary:   Quality of Life Assessed by MOS-HIV (Medical Outcome Study-HIV) Questionnaire   [ Time Frame: Baseline and at 6 months after treatment ]

4.  Secondary:   Number of Participants With Global Esthetic Improvement   [ Time Frame: One month and up to 18 months after treatment ]

5.  Secondary:   Number of Participants With Gel Displacement Evaluated by Magnetic Resonance Imaging (MRI)   [ Time Frame: 12 months after treatment ]

6.  Secondary:   Adverse Event Recording   [ Time Frame: Up to 18 months after treatment ]

7.  Secondary:   Time Until it Became Impossible to Stay Sitting   [ Time Frame: Baseline and at 6 months after treatment ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information